The US Food and Drug Administration (FDA) has granted 510(k) clearance to market GenMark Diagnostics’ ePlex instrument and respiratory pathogen (RP) panel.

ePlex is an in-vitro diagnostic platform that combines a fully automated, sample-to-answer system with nucleic acid extraction, amplification and detection processes.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

To enable quick and precise detection, the platform features the eSensor technology, which has been used on the firm’s XT-8 system for more than two million patient tests performed with various FDA-cleared panels.

The ePlex RP panel is designed to detect more than 20 viral and bacterial pathogens that are known to cause upper respiratory infections.

The combination of the RP panel with true sample-to-answer capabilities of ePlex is expected to allow quick, precise and actionable test results for high-risk patients, as well as enable improvement of productivity through decreased labour costs, advanced data analytics, customer service, and support.

"It is the only sample-to-answer molecular platform that integrates the diagnostic process from test order entry, all the way to reporting actionable results."

GenMark president and CEO Hany Massarany said: “There is a growing body of evidence that rapid, multiplex molecular testing for respiratory pathogens improves patient outcomes, reduces total cost of care, and enhances key quality metrics.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

“We believe that ePlex will help laboratories and hospitals realise these benefits as it is the only sample-to-answer molecular platform that integrates the diagnostic process from test order entry, all the way to reporting actionable results.”

It is anticipated that the launch of ePlex will bolster the benefits of multiplex molecular testing and make them accessible to several hospitals and patients in the US.

GenMark has previously announced the signing of more than 70 ePlex customer agreements accounting to more than 100 analysers.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact